AN OPEN-LABEL, SINGLE-TREATMENT, SINGLE-PERIOD, SINGLE DOSE, CLINICAL PHASE 1 STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF TYPHOID (Vi CAPSULAR POLYSACCHARIDE) TETANUS TOXOID CONJUGATE VACCINE OF M/s CADILA HEALTHCARE LTD., INDIA IN HEALTHY, ADULT, MALE, HUMAN SUBJECTS. - TYTTSD 1001

Trial Profile

AN OPEN-LABEL, SINGLE-TREATMENT, SINGLE-PERIOD, SINGLE DOSE, CLINICAL PHASE 1 STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF TYPHOID (Vi CAPSULAR POLYSACCHARIDE) TETANUS TOXOID CONJUGATE VACCINE OF M/s CADILA HEALTHCARE LTD., INDIA IN HEALTHY, ADULT, MALE, HUMAN SUBJECTS. - TYTTSD 1001

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Typhoid vaccine Vi conjugate (Primary)
  • Indications Tetanus; Typhoid
  • Focus Adverse reactions
  • Sponsors Cadila Healthcare
  • Most Recent Events

    • 07 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top